Disease Diagnosis TRIZ Cases

In situ nanoshells form around exosomes to enable optical signal measurement and target identification via fluorescence quenching.

Measuring anti-EGF autoantibodies via immunoassay to diagnose ovarian cancer and predict treatment response when CA125 biomarkers lack precision.

A multiplexed mass spectrometry platform detects multiple metabolites from a single dried blood spot without conventional buffering systems.

A diagnostic kit detects specific protein concentrations in blood samples to identify endometriosis without invasive surgery.

Detecting anti-moesin antibodies provides a novel pathological marker that overcomes the limited diagnostic accuracy of MPO-ANCA testing.

Blood amino acid concentration data enables accurate evaluation of fatty liver related diseases through multivariate discriminant analysis.

Elevated neurofilament levels serve as biomarkers for progressive multifocal leukoencephalopathy risk assessment.

An immunoassay using a monoclonal antibody detects specific elastin degradation markers, enabling early COPD diagnosis without invasive procedures.

Segmented biomarkers predict survival and tumor response, resolving prediction reliability gaps.

Blood-based IL-1 signaling molecules predict therapeutic responsiveness to immune checkpoint inhibitors.

Recombinant antibody technology resolves low yield and high production costs of hybridoma methods by expressing optimized HRP-II binding sequences in CHO cells.

Protein biomarker panels identify stroke by measuring GFAP, b-NGF, and vWF concentrations to resolve diagnostic accuracy versus time delays.

Measuring platelet activity before therapy administration predicts clopidogrel resistance, eliminating diagnostic delays and reducing thrombotic events.

Analysis unit calculates parameter R from temporal electrical characteristic changes to acquire fibrinogen information.

PYPQQQQPY peptide sequences detect gluten-reactive T cells, resolving low sensitivity and cumbersome procedures in celiac disease diagnosis.

A test kit selects food preparations using discriminatory p-values to measure IgG binding for irritable bowel syndrome diagnosis.

Buffered galactose solution with antioxidants maintains stability for accurate liver function testing without invasive intravenous injections.

A biosensor system detects biomarkers using electrical impedance spectroscopy signals measured from a functionalized carbon nanoparticle paste.

Extracting toxic microparticles via immunomagnetic separation prevents vaso-occlusive crises without transfusion risks.

Quantifying soluble CD27 levels in patient plasma to determine response likelihood for anti-PD-1 and anti-PD-L1 treatments.

Analyzing Ambra-1 and Loricrin expression in tissue samples predicts metastasis risk, enabling early intervention to delay disease progression.

Replacing invasive radiologic imaging, flow cytometry measures NKG2D ligand levels in blood to assess recurrence risk and guide treatment regimes.

A microfluidic sample device isolates target analytes from biological fluids using magnetic beads and adsorbent units.

In vitro method quantifies procalcitonin levels to predict adverse events in asymptomatic subjects.

Affinity reagents capture GP2a protein from patient samples to enable rapid in vitro diagnostic testing.

Disposable screen-printed electrodes eliminate washing steps to enable high-throughput tuberculosis diagnosis without complex biosensor maintenance.

Anti-carbamylated protein IgA antibodies detect rheumatoid arthritis risk through specific biomarker profiling.

A 20-antibody cocktail enables simultaneous detection of multiple B-cell markers in a single tube assay.

Specific monoclonal antibodies detect FMRP without cross-reactivity, enabling rapid diagnosis of Fragile X syndrome in standard laboratories.

Measuring heart-type fatty acid binding protein levels resolves diagnostic reliability versus treatment delay contradictions in ischemic stroke evaluation.

Segmenting diagnosis into a metabolite panel resolves CEA reliability limits, enabling precise CRC detection and monitoring.

Combining copeptin, troponin, and BNP measurements resolves the trade-off between diagnostic sensitivity and system complexity for early MACCE detection.

Type I CP-673,451 targets active FLT3 conformations to overcome resistance mutations that limit Type II inhibitors.

Albumin stabilizes gangliosides at room temperature, eliminating cooling needs while maintaining autoantibody detection reliability.

A urinary biomarker panel detects active lupus nephritis using Adiponectin, MCP-1, sVCAM-1, and PF4 agents.

Detecting five specific urinary proteins replaces invasive nuclear medicine imaging, enabling non-invasive diagnosis of congenital renal dysfunction.

Single device merges collection and testing via absorbent pads, eliminating separate instruments and harmful chemical exposure.

Plasma metabolites and glycans predict viral rebound timing, eliminating costly analytical treatment interruptions.

Measuring progastrin levels identifies early tumor progression before clinical symptoms appear, bypassing the imprecision of TNM staging systems.

Measuring 5-methoxytryptophan via competitive ELISA resolves insufficient cytokine accuracy for predicting sepsis and systemic lupus severity.

Comparing IGFBP2 levels against thresholds derived from NYHA stages resolves the contradiction between diagnosis facilitation and biomarker accuracy.

Miox antibodies measure myo-inositol oxygenase levels to detect acute kidney injury before serum creatinine rises, overcoming non-specific diagnostic delays.

Antibody cocktail identifies multiple antigens simultaneously in tissue sections to distinguish adenocarcinoma from squamous cell carcinoma.

Specific peptides immobilized on carriers detect AOSD antibodies, distinguishing the disease from other febrile conditions.

Antibodies detect gluten peptides in urine, replacing invasive biopsies to monitor diet adherence.

Multi-frequency impedance measurement in a biosensor detects low-concentration antigens, resolving the trade-off between precision and system complexity.

Isolated polypeptides from nucleocapsid or spike protein domains bind anti-beta-coronavirus antibodies to enable specific detection and quantification.

A defined suspension medium supports rapid tumor cell cluster proliferation without extracellular matrix embedding.

A portable automated system analyzes blood chemistry parameters to determine patient resuscitatability status.